摘要
目的 评价血清可溶性肿瘤坏死因子受体Ⅰ (STNFR -Ⅰ )检测的临床应用价值。方法 采用酶联免疫吸附法 (ELISA)对 6 2例肺癌患者及 6 1例健康人进行了STNFR -Ⅰ的测定。结果 肺癌组STNFR -Ⅰ值为 2 .84± 1.8ng/ml,高于健康对照组 0 .93± 0 .2 9ng/ml,两组比较P <0 .0 1,且STNFR -Ⅰ水平随肺癌病期进展而升高 ,Ⅰ、Ⅱ、Ⅲ、Ⅳ期分别为 2 .2 3± 0 .47μg/L、2 .34± 0 .6 8μg/L、2 .6 3±0 .6 7ng/ml、3.5 1± 1.6 2 μg/L。肺癌患者STNFR -Ⅰ阳性率 (80 .7% )超过了血清癌胚抗原 (CEA)的阳性率 (38.7% )。结论 测定血清中STNFR -Ⅰ对肺癌的诊断、分期和预后均有较为实用的临床应用价值。
Objective To evaluate the clinical value of serum soluble tumor necrosis factor receptor Ⅰ(STNFRⅠ) in patients with lung cancer. Methods Detected STNFRⅠlevel in 62 cases with lung cancer and 61 healthy adults as controls with ELISA assay. Results STNFRⅠlevel in lung cancer group was significantly increased compared with controls (2.84±1.18μg/L versus 0.93±0.29μg/L, P<0.01). STNFRⅠlevel was escalated along with clinical stages (2.23±0.47μg/L, 2.34±0.68μg/L,2.63±0.67μg/L,3.51±1.62μg/L in stage Ⅰ,Ⅱ,Ⅲ,Ⅳ,respectively). The positive rate of STNFRⅠlevel in lung cancer group was 80.7%, which greatly exceeded the conventional marker-CEA(38.7%). Conclusion STNFRⅠ detection is higher clinical value in diagnosis, classification and prognosis of lung cancer.
